Сравнение
Goserelin vs. Pasireotid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
65807-02-5
396091-73-9
Молекулярная масса
1269.43 g/mol
1047.21 g/mol
Период полувыведения
4.2 h
нет данных
Последовательность
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2нет данных
Механизм действия
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
1
из них на людях
4
1
Зафиксированные эффекты
3
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
2
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Goserelin and Pasireotid?
- Goserelin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Pasireotid?
- The highest available evidence level is "РКИ на людях" for Goserelin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Pasireotid in Germany and the United States?
- Германия: Goserelin — Рецептурный, Pasireotid — Рецептурный. США: Goserelin — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.